Meet Our Consultancy Team

Experience: Executive and scientific leader with 20+ years of experience in drug discovery and development. Proven track record of advancing first-in-class and best-in-class therapeutics with >10 INDs.

Expertise: Small molecules, biologics, ADCs, translational oncology, preclinical pharmacology, PDX, organoids, IO systems.

Experience: Scientific leader with 20+ years in the industry spanning from preclinical to early clinical development. Led preclinical and clinical evaluation of oncology and IO programs, from preclinical through Phase I/Iia.

Expertise: IO, PDX, humanized mice, organoids, NAMs, translational oncology, non-clinical pharmacology, regulatory documentation.

Experience: Scientific leader with >8 years of experience directing preclinical pharmacology strategies across small molecules, ADCs, and biologics, from target validation through IND-enabling studies, contributing to 9 IND submissions.

Expertise: Oncology and IO, in vivo pharmacology (syngeneic, xenograft, PDX, humanized mouse models, and GEMMs), mechanism of action, PK/PD analysis, biomarker strategies, and translational oncology.

Experience: Executive and scientific leader with 20+ years of experience in the CRO and biotech sectors across preclinical and translational oncology drug development. Founder and entrepreneur, driving innovation, integration and commercial success.

Expertise: Small molecules, biologics, cell therapies. In vitro, in vivo and ex vivo pharmacology, cell and molecular biology, patient-derived systems (PDX, organoids), in vivo imaging, and cross-disciplinary drug discovery/development strategy

Experience: Executive-level translational pharmacology and oncology leader with 20+ years of experience with direct contributions to the development of marketed targeted anticancer therapies and global scientific consultancy leadership.

Expertise: Cell biology, in vivo pharmacology, imaging, and preclinical efficacy/safety assessment across small molecules and biologics.